A few hundred million? I wish you are on target, but Mr. Market has different thoughts.
In my opinion, the market is pricing in a deal. The problem is where does Kazia go from that point? Cantrixil is a phase 1 candidate that can hit...or miss. Kazia is no longer a drug discovery biotech....there lies the uncertainty. With that said Kazia shares are still undervalued IMO
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
A few hundred million? I wish you are on target, but Mr. Market...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)